Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06837077
PHASE1

Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration. The study aims to compare the safety and pharmacokinetics data to assess feasibility of single-site and multiple-site injection for administration.

Official title: A Single-center, Randomized, Crossover, Open-label Phase I Study to Compare the Safety and Pharmacokinetics of SHR-1209 Given as Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

46

Start Date

2025-03-14

Completion Date

2025-07

Last Updated

2025-06-24

Healthy Volunteers

Yes

Interventions

DRUG

SHR-1209 single-site subcutaneous injection

SHR-1209 single-site subcutaneous injection.

DRUG

SHR-1209 multiple-site subcutaneous injections

SHR-1209 multiple-site subcutaneous injections.

Locations (1)

The First Affiliated Hospital of USTC

Hefei, Anhui, China